Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies

Lucas Pacoureaua Assistance Publique - Hôpitaux de Paris, Department of Internal Medicine and Clinical Immunology, Bicetre Hospital, Le Kremlin Bicêtre, France;

Mathilde De Menthona Assistance Publique - Hôpitaux de Paris, Department of Internal Medicine and Clinical Immunology, Bicetre Hospital, Le Kremlin Bicêtre, France;

Isabelle Boytchevb Assistance Publique - Hôpitaux de Paris, Department of Gastroenterology, Bicetre Hospital, Le Kremlin BIcêtre, France;

Thierry Lazurec Assistance Publique - Hôpitaux de Paris, Department of Pathology, Bicetre Hospital, Le Kremlin BIcêtre, France;

Laurence Rocherd Assistance Publique - Hôpitaux de Paris, Department of Radiology, Antoine Beclere Hospital, Clamart, France;;e Paris Saclay University, Le Kremlin Bicêtre, France;

Olivier Lambottea Assistance Publique - Hôpitaux de Paris, Department of Internal Medicine and Clinical Immunology, Bicetre Hospital, Le Kremlin Bicêtre, France;;e Paris Saclay University, Le Kremlin Bicêtre, France;;f INSERM UMR 1184 Unit, Center for Immunology of Viral and Autoimmune Diseases, Paris Saclay University, Le Kremlin-Bicêtre, France;;g Commissariat à l'Energie Atomique (CEA), Division of Immuno-Virology, IDMIT, Fontenay-aux-Roses, France

Nicolas Noëla Assistance Publique - Hôpitaux de Paris, Department of Internal Medicine and Clinical Immunology, Bicetre Hospital, Le Kremlin Bicêtre, France;;e Paris Saclay University, Le Kremlin Bicêtre, France;;f INSERM UMR 1184 Unit, Center for Immunology of Viral and Autoimmune Diseases, Paris Saclay University, Le Kremlin-Bicêtre, France;;g Commissariat à l'Energie Atomique (CEA), Division of Immuno-Virology, IDMIT, Fontenay-aux-Roses, FranceCorrespondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Disclosure statement

Dr NOEL reports speaker fees from MSD outside the submitted work.

Prof. LAMBOTTE reports grants from Gilead, personal fees and nonfinancial support from BMS, personal fees from MSD, Astra Zeneca, Incyte, and Janssen, and nonfinancial support from LFB and CSL Behring outside the submitted work.

Other authors: nothing to disclose.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies

Information for

Open access

Opportunities

Help and information

Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature